Creative Biolabs AI Accelerates Multi-Receptor Agonist Design

SHIRLEY, NY — As the pharmaceutical industry races to develop next-generation metabolic therapies following the success of GLP-1 drugs, Creative Biolabs has unveiled an upgraded AI-driven platform designed to accelerate the computational design of multi-receptor agonists. The company’s new deep learning algorithms allow researchers to screen millions of peptide sequences rapidly, targeting dual and triple-receptor combinations such as GLP-1/GIP/GCGR for obesity and type 2 diabetes. This innovation directly addresses the bottleneck of optimizing polypharmacology—balancing activation ratios across multiple receptors—which traditionally takes years of trial and error. By simulating receptor-ligand interactions in a high-throughput virtual environment, the platform identifies promising molecules in as little as 2 to 14 weeks, drastically shortening the timeline from hit identification to lead optimization.

Creative Biolabs also tackles key industry challenges like peptide half-life and data quality. Their AI infrastructure calculates and eliminates vulnerable sequence sites to engineer ultra-long-acting profiles, reducing dosing frequency for patients. To overcome the “garbage in, garbage out” problem, the platform relies on high-fidelity pharmacological dataset training, using curated, function-first data to accurately predict ADMET properties early in development. This ensures generated sequences are potent and free from severe off-target toxicity or immunogenicity. Additionally, the platform integrates molecular dynamics simulations for targeting hidden binding pockets via allosteric modulation, allowing precise fine-tuning of receptor activity without overstimulating homologous proteins.

“Industrial clients require more than just theoretical binding affinity; they demand manufacturable, highly stable molecules with guaranteed functional activity in biological assays,” said the director of computational biology at Creative Biolabs. Pharmaceutical partners report significant reductions in design-test-learn cycles, highlighting the platform’s predictive accuracy and comprehensive deliverables that bridge in silico predictions with in vitro success. Biotechnology firms and pharmaceutical companies developing pipeline assets for complex metabolic disorders are encouraged to explore these advanced workflows. For technical specifications or project consultations, visit Creative Biolabs' official platform.